Pre-Conference Workshop Day

Tuesday, January 26, 2021

Pre-conference working groups are extended, educational and interactive sessions. Inclusive of case studies, experience led presentations, audience discussion and group exercises to deepen your understanding and give you actionable insights to advance your TGF-ß candidates.

Workshop A

TGFß Boot Camp: Roles of TGFß in Carcinomas

10:00 - 12:00 EST | 7:00 - 9:00 PST

With the success of immunotherapies, such as anti-PD-1/PD-L1 and anti-CTLA4, TGFß signaling has
shown itself as a major impediment of success of immunotherapies. Hence, TGFß is now seen with highly
promising potential to drug developers, as a blockbuster checkpoint combination for novel Immuno-oncology treatment. However, thinking of TGFß as a simple on/off switch is not appropriate, and
thoughtful approaches toward targeted TGFß inhibition are required for a next generation of successful combination therapeutics.

Prior to main conference case studies, this pre-conference primer will explore TGFß’s role in normal physiology, in cancer cells and in the tumor micro-environment, including its key roles in cancer-associated immunosuppression. We will delve into the signalling mechanisms of TGFß, why blocking TGFß systemically is likely to result in systemic adverse effects, and discuss how TGFß can act as a driver of tumor progression.

Workshop Leader

Rik Derynck UCSF

Rik Derynck
Professor - Departments of Cell, Tissue Biology & Anatomy
University of California San Francisco

Workshop B

Translating TGFß into the Clinic

13:00 - 15:00 EST | 10:00 - 12:00 PST

Wondering how to successfully translate your candidate into the clinic? With a narrow therapeutic window and high potency, a good understanding of your mechanisms of action and a detailed dosing regime is
required. However, what data are regulators looking for from a tox and efficacy standpoint, how does this impact small molecule or antibody approaches? This working group will detail the key considerations in your trial design, patient stratification, and tox data to minimize adverse risk to patients.

Workshop Leaders

James Gulley

James Gulley
Chief, Genitourinary Malignancies Branch Head, Immunotherapy Group, GMB Director, Medical Oncology Service
Center for Cancer Research, NCI, NIH

Julius Strauss

Julius Strauss
Co-Director Laboratory of Tumor Immunology & Biology
Center for Cancer Research, NCI, NIH